论文部分内容阅读
Lacidipine(简称LAC)是一新的长效双氢吡啶类钙抗剂,具有选择性扩周围血管作用和每日一次给药之优点。本文评价口服LAC对高血压病人24小时动脉内血压及生理试验时血压的影响。方法 12例未经治疗的高血压病人。所有病人先插入动脉导管并行24小时动脉内血压监测,然后给予首剂LAC4mg,并再行24小时动脉内血压监测。拔出动脉导管后,病人继续在上午10时口服LAC4mg每日1次。2周后,血压控制满意者,继续服上述剂量至少2周;血压控制不满意者,剂量增至每日6mg,2周后,血压仍未控制者,则剂量再增至每日8mg。所有病人服用固定剂量
Lacidipine (LAC) is a new long-acting dihydropyridine calcium antagonist that has the advantage of selective peripheral vasodilation and once-daily administration. This article evaluates the effects of oral LAC on blood pressure in patients with essential hypertension at 24-hour arterial pressure and at physiological tests. Methods Twelve untreated hypertensive patients. All patients were first catheterized into the arterial catheter for 24-hour arterial blood pressure monitoring, and then given the first dose of LAC4mg, and then 24-hour arterial blood pressure monitoring. After pulling out the arterial catheter, the patient continued oral LAC 4 mg orally once daily at 10 a.m. After 2 weeks, those with satisfactory blood pressure control continued to take the above dose for at least 2 weeks. Those who were not satisfied with blood pressure control increased their dose to 6 mg daily. After 2 weeks, the blood pressure was still not controlled, and the dose was increased to 8 mg daily. All patients take a fixed dose